AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04038671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activated Carbon Cloth Dressing
Description: Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
Study NCT04038671 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Knitted Cellulose Acetate Mesh
Description: Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
Study NCT04038671 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial Alginate Dressing with Silver
Description: Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
Study NCT04124471 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Open-ended semi-structured interviews
Description: Semi-structured interviews will explore such key constructs as knowledge/belief about OSAS and PAP therapy, routines and resources that promote or limit PAP use, barriers, self-efficacy, and communication and attitudes about PAP. The interviews will be performed with the parent and that they will be audio-recorded.
Study NCT02712190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency non-invasive ventilation
Description: Comparison of 2 different settings of HF-NIV
Study NCT05708313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification
Description: Participants will undergo an exercise program designed by AHH
Study NCT01991925 — intervention group
Intervention type: OTHER
Intervention: Interviews, questionaires, RAND-modified delphi method round
Description: phase 1: RAND-modified delphi method round with experts in hereditary haemochromatosis phase 2: patient interviews, questionnaires and focus group interviews
Study NCT03216941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: study medications were packaged in identical color-coded boxes. first dosage included either 10 mg of olanzapine, or 10 mg of ketamine Dosages were chosen based on previous studies After the initial dose, no additional dosis were allowed if supplemental medication eas needed according to clinician judgment the subject will be immediately removed from the study.~All subjects will be assessed 1 hour, 2 hours, 4 hours, 6 hours and 12 hours after t he first administration of the medication.
Study NCT00960505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate day fasting
Study NCT00960505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie restriction
Study NCT00960505 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Study NCT04633785 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There are no interventions in this study. The mercury sphygmomanometer and the wrist sphygmomanometer will be used in this study to collect blood pressure values from the study subjects.
Study NCT02325583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% Glucose
Description: ORAL 30% GLUCOSE 0,5-2 ML
Study NCT02325583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: INTRAVENOUS 0.1 MG/KG MIDAZOLAM
Study NCT03025997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active yoghurt
Description: Active yoghurt (containing encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
Study NCT03025997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yoghurt
Description: Placebo yoghurt (containing non-encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
Study NCT04106453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: navigated microwave ablation
Description: the laparoscopic microwave ablation in the pig liver is performed with the CasOne-Spot system
Study NCT04106453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided navigation
Description: the laparoscopic microwave ablation iin the pic liver is performed with ultrasound guidance
Study NCT01216059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Text message to cell phone
Description: Subjects will receive a daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study
Study NCT03751553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obsteric gel(k-Y jelly)
Description: A sterile obstetric gel( K-Y Jelly 82GM; manufactured by Johnson\&amp; Johnson) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that have purely physical activity. Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child manually or using the sterile obstetric gel applicator without any manipulation or massage.
Study NCT01734473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein protein
Description: Amount provided is based on the fat-free mass of subject
Study NCT01734473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein protein + carbohydrates
Description: Amount provided is based on the fat-free mass of subject
Study NCT01734473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein protein + leucine
Description: Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
Study NCT01734473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein protein + carbohydrates + leucine
Description: Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
Study NCT01734473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4 levels of hydrolyzed casein protein + carbohydrates
Description: Amount provided is based on the fat-free mass of subject. The 4 levels are: 0, 0.02, 0.05, 0.15 g casein protein/kg fat free mass/hr. The ratio between protein and carbohydrates is fixed.
Study NCT01878383 — intervention group
Intervention type: DEVICE
Intervention: Genexpert assay
Study NCT04590950 — intervention group
Intervention type: OTHER
Intervention: Non interventional study
Description: Non interventional study
Study NCT02628964 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: e-cigarettes
Description: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.
Study NCT02628964 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: e-cigarettes
Description: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.
Study NCT00552513 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Early Coronary Intervention
Description: Perform coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) as soon as possible (and within 24 hours of randomisation).
Study NCT00552513 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Delayed Coronary Intervention
Description: Perform coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) any time after 36 hours after randomisation.
Study NCT00675038 — intervention group
Intervention type: PROCEDURE
Intervention: Liver Biopsy and MRI T2* MRI
Description: Evaluation of iron overload with liver biopsy vs. MRI T2\* MRI
Study NCT02720185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100mg oral once daily dasatinib taken for 7-10 days up to the day prior to planned surgery or research biopsy (neoadjuvant chemotherapy group)
Study NCT02720185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery
Study NCT02720185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01865500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 4 mg
Description: It will be evaluated at baseline, 24 h, 48 h and before discharge
Study NCT01865500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 8 mg
Description: Baseline FEV1 and before discharge FEV1 were evaluated
Study NCT01865500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metil prednisolone
Study NCT03466879 — intervention group
Intervention type: DEVICE
Intervention: SYNUS Pain Relief device
Description: SYNUS Pain Relief is a handheld micro-current TENS device used for the temporary relief of sinus pain.
Study NCT05558800 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Implant placement
Description: Implant placement with different surface types
Study NCT05558800 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Implant placement with different surface types
Study NCT01608516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-RGD PET/CT
Description: 200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired
Study NCT01918072 — intervention group
Intervention type: OTHER
Intervention: Clinical innovation
Description: Technology-based intervention that combines interactive communication with women's health specialists and ongoing education
Study NCT04517773 — intervention group
Intervention type: OTHER
Intervention: writting test
Description: Patients will be invitated to fill a questionary about self-autonomy
Study NCT04260386 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: During the cardiac arrest scenario, the delegates observing will be asked to refer to the maternal cardiac arrest proforma and record those details of events that they are able to see/hear from the video link. In addition, the proforma will be provided to the team taking part in the simulation. One or more team members would routinely be given the role of 'scribe', recording events as they occur. The proforma is accompanied by explanatory notes on how to use it.~Delegates (observers plus scribes) will then be asked to complete a questionnaire, seeking their opinions on the usefulness of the proforma. Questionnaires will be linked to the written consent forms by a participant ID number.
Study NCT03142373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CV4 technique
Study NCT03142373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RR technique
Study NCT03142373 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Study NCT04283526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Intravenous. 600mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).
Study NCT04283526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Intravenous. 2100mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).
Study NCT04283526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Intravenous. 300mg. Every first day of a 21-day cycle
Study NCT04283526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Intravenous. Starting dose: 5mg/m2 (dose cap at 20mg/m2). On days 1, 2 and 3 of a 42-day cycle
Study NCT02658708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright blue-green light using light visor cap
Study NCT02658708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dim red light using light visor cap
Study NCT02658708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire
Description: -Consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life
Study NCT02658708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire
Description: -Consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life
Study NCT02658708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale
Description: -Consists of 8 common daily activities with a 4-point rating scale (0=would never doze to 3=a high chance of dozing) measuring usual daytime sleepiness over a recent time period
Study NCT02658708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epworth Sleepiness Scale
Description: -Consists of 8 common daily activities with a 4-point rating scale (0=would never doze to 3=a high chance of dozing) measuring usual daytime sleepiness over a recent time period
Study NCT02658708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index
Description: -Contains 19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance
Study NCT02658708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pittsburgh Sleep Quality Index
Description: -Contains 19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance
Study NCT02658708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance
Description: -Consists of 8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances
Study NCT02658708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance
Description: -Consists of 8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances
Study NCT02658708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue
Description: -Consists of 8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue.
Study NCT02658708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue
Description: -Consists of 8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue.
Study NCT02658708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Digital foot candle datalogging light meter (Extech Instrument, Model SDL400)
Description: -The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck.
Study NCT02658708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Digital foot candle datalogging light meter (Extech Instrument, Model SDL400)
Description: -The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck.
Study NCT02658708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA)
Description: -A standard sleep montage of electroencephalography following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed
Study NCT02658708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA)
Description: -A standard sleep montage of electroencephalography following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed
Study NCT02658708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Horne-Ostberg Morningness-Eveningness Questionnaire
Study NCT00381888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux sodium
Description: Fondaparinux, 2.5 mg subcutaneous, Days 1-28 by mouth.
Study NCT01583738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0251
Description: single dose
Study NCT01583738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose
Study NCT02645539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravascular ventricular assist system (iVAS)
Description: A mechanical circulatory support device using the principles of counterpulsation.
Study NCT00709540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-011 or placebo
Description: multiple administrations of ACE-011 given subcutaneously once per month for 3 months (4 administrations total)
Study NCT00854971 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TKCell
Description: Biological/Vaccine: TKCell
Study NCT02007811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic donor derived B-lymphocytes
Description: CD3+-depleted, CD19+-enriched, cryopreserved (single administration after day 120 following allogeneic stem cell transplantation, donor-identical) in 4 groups with escalating doses
Study NCT02983877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iTAB-CV
Description: Stage 1 of the intervention will be introduced. Researchers will conduct an interview in order to customize iTAB-CV for each participant at the baseline session. In the first month, participants will receive alternating daily texts with educational and motivational content and a daily mood rating request to both monitor their mood and to determine adherence to the intervention.~In the second stage for the following month, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from stage 1.
Study NCT00945113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-week speech therapy group
Description: One-week cross-district speech therapy group for older children (aged 8 to 15) who stammer
Study NCT01101334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-7017
Description: CS-7017, Two 0.25mg Tablets administered twice daily
Study NCT01101334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Erlotinib; One 150mg tablet administered once daily
Study NCT01101334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: Erlotinib; One 150mg tablet administered once daily
Study NCT01391676 — intervention group
Intervention type: PROCEDURE
Intervention: trabeculectomy
Description: postoperative imaging of trabeculectomy blebs with the spectral domain optical coherence tomography
Study NCT01837498 — intervention group
Intervention type: DRUG
Intervention: Neostigmine
Description: At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
Study NCT01837498 — intervention group
Intervention type: DRUG
Intervention: Sugammadex
Description: At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
Study NCT00610571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Topotecan and Temodar
Description: Temozolomide is taken by mouth once day, every day for 5 consecutive days at dose of 200 mg/m2/day.~Oral Topotecan will be taken daily for 5 consecutive days beginning 12-24 hrs after 1st dose of Temozolomide. Dose escalation of Oral Topotecan will be carried out in cohorts of 3 new subjects beginning w dose level 1 @ 0.75 mg/m2/dose.
Study NCT01502306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: Telephone counseling is conducted in the appropriate language (Spanish and English) by counselors at the California Smokers' Helpline. Counselors use a structured protocol and there is a record for each call. Quantitative information that will be available for analysis include: timing, length, and frequency of counseling calls.